IdorsiaXSWX:IDIA +13.95%48 Days Payable is 231.08 as of Mar. 2026, which is 71% below its 10-year median of 808.39. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.85 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Idorsia ranks better than 69.59% on this metric.
Idorsia's average Accounts Payable for the
three
months ended in Mar. 2026 was CHF20.4 Mil. Idorsia's Cost of Goods Sold for the
three
months ended in Mar. 2026 was CHF8.1 Mil.
Hence, Idorsia's Days Payable for the
three
months ended in Mar. 2026 was 231.08.
The historical rank and industry rank for Idorsia's Days Payable or its related term are showing as below:
XSWX:IDIA'
s Days Payable Range Over the Past 10 Years
Min: 279.86 Med: 808.39 Max: 1523.11
Current: 285.58
During the past 10 years, Idorsia's highest Days Payable was 1523.11. The lowest was 279.86. And the median was 808.39.
XSWX:IDIA's Days Payable is ranked better than 69.59% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs XSWX:IDIA: 285.58
Idorsia's Days Payable
declined
from Mar. 2025 (1,124.96) to Mar. 2026 (231.08).
It may suggest that Idorsiaaccelerated paying its suppliers.
Idorsia Days Payable Related Terms
Idorsia Days Payable Historical Data
* Premium members only.
The historical data trend for Idorsia's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Idorsia's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Days Payable distribution charts can be found below:
* The bar in red indicates where Idorsia's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Idorsia's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a Days Payable of 231.08 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Idorsia and its competitors. This is 71% below median its historical median of 808.39. Over the past decade, Idorsia's Days Payable has ranged from 279.86 to 1,523.11. According to the industry distribution chart, Idorsia ranks #215 out of 707 companies in the Biotechnology industry, placing it in the top 30.4%.
Is Idorsia's Days Payable too high?
Idorsia's current Days Payable of 231.08 is 71% below median its 10-year median of 808.39. Over the past 10 years, this metric has ranged from a low of 279.86 to a high of 1,523.11. The Biotechnology industry median Days Payable is 113.76. Idorsia's value of 231.08 is 103.1% above this industry median. Based on the distribution chart, Idorsia ranks #215 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #215 out of 707 companies for Days Payable. This puts Idorsia in the upper half of its industry. The industry median Days Payable is 113.76. Idorsia's value of 231.08 is 103.1% above this benchmark. Historically, Idorsia's own Days Payable has ranged from 279.86 to 1,523.11 over the past decade. While the company's 10-year median is 808.39 vs. the industry median of 113.76, Idorsia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Idorsia's current Days Payable of 231.08 is 103.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Idorsia and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current Days Payable is 231.08, which is 71% below median its own 10-year median of 808.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.85, compared to a current price of CHF6.86 — trading 140.7% above its estimated fair value. The current Days Payable is 231.08, which is 71% below median its 10-year median of 808.39 and 103.1% above the Biotechnology industry median of 113.76. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Days Payable is 231.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.86 is trading 140.7% above its estimated GF Value™ of CHF2.85.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Days Payable: 231.08 (71% below median its 10-year median of 808.39)
GF Value™: CHF2.85 vs. price of CHF6.86 (140.7% above fair value)
Industry Position: 103.1% above the Biotechnology median (#215 of 707)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
